Association of Serum Osteocalcin with Insulin Resistance and Coronary Atherosclerosis

Jee-Hyun Kang
Department of Family Medicine, Konyang University Hospital, Daejeon, Korea

Background: To determine the associations between serum osteocalcin level and insulin resistance, coronary atherosclerosis by using dual-source coronary computed tomography angiography. Methods: A total of 98 subjects (24 men and 74 women) were selected for this retrospective cross-sectional study who voluntarily visited a health examination center for routine health check-up including the blood test for serum osteocalcin level and coronary computed tomography angiography. Multiple regression analysis was used to determine which variables were independently related to osteocalcin levels and coronary atherosclerosis. Results: Stepwise multiple regression analysis adjusted for age, sex, menopausal status, body mass index, serum alkaline phosphatase, serum calcium and phosphate showed that osteocalcin negatively correlated with serum glucose (β = -0.145, P = 0.001) and homeostasis model assessment of insulin resistance (HOMA-IR) index (β = -1.794, P = 0.027) independently. The age, serum glucose, smoking status but not osteocalcin level were independent risk factors for coronary atherosclerosis by use of multiple logistic regression analysis after controlling for other variables. Conclusions: Serum osteocalcin level was inversely associated with fasting glucose level and insulin resistance measured by HOMA-IR, suggesting that osteocalcin is important for glucose metabolism. However, in this study, no significant difference was observed in the serum osteocalcin level according to the presence of coronary atherosclerotic plaques.

Key Words: Coronary angiography, Coronary artery disease, Insulin resistance, Osteocalcin

INTRODUCTION

Osteocalcin, a bone-derived protein secreted by osteoblasts, is a bone formation marker, also known as a marker for bone turnover. It has been used clinically to assess the effectiveness of osteoporosis treatments.

Recently, it has been discovered that osteocalcin also acts as a hormone to control glucose and energy metabolism on pancreatic β-cells and adipose and muscle tissues.[1]

In one animal experiment, genetically modified mice were not able to secrete osteocalcin while exhibiting decreased β-cell proliferation, glucose intolerance and insulin resistance.[2] When recombinant osteocalcin was injected into the wild-type mice, an increase in pancreatic β-cell proliferation, insulin secretion and a reduction in body fat were observed.[3] In addition, in a cross-sectional and a pro-
spective study involving human subjects, serum osteocalcin concentration was observed to be inversely correlated to fasting blood glucose, insulin resistance, and body fat mass.[4,5]

Moreover, osteocalcin has been receiving much attention for being an indicator of cardiovascular diseases. Recent studies have reported that serum osteocalcin concentration may be associated with calcification of the coronary arteries and the aorta, thickness of the intima-media of the carotid artery, and formation of atherosclerotic plaques in the carotid artery.[6-9] Although these studies have shown that osteocalcin concentration in the blood may be independently correlated with increased risk of cardiovascular diseases, the results lack consistency; there have been other reports suggesting no relation of osteocalcin to the incidence of cardiovascular diseases.[10]

With the recent and rapid development of multidetector computed tomography (MDCT), coronary computed tomography (CT) angiography through MDCT has been widely used to detect the presence of atherosclerotic plaques in the coronary arteries and to assess the degree of stenosis.

This study investigates the relationship between serum osteocalcin level and insulin resistance measured by using the homeostasis model assessment of insulin resistance (HOMA-IR) index, as well as the relationship between the presence of atherosclerotic plaques in the coronary arteries by using coronary CT angiography and osteocalcin concentration.

METHODS

1. Study subjects

We retrospectively collected study subjects aged over 20 years who had simultaneously undergone coronary CT angiography and blood test including serum osteocalcin, glucose, insulin, calcium, phosphorus, lipids and alkaline phosphatase (ALP) for routine health check-up from January 2012 to December 2015. A total of 98 people (24 men and 74 women) who visited a health promotion center voluntarily included as subjects. Their medical records were investigated in a retrospective manner.

Subjects were excluded if their medical records and questionnaires indicated that they were taking medications or health supplements that could affect their bone and mineral metabolism, such as hormones, osteoporosis medica-

tions, or calcium and vitamin D supplements. They were also excluded if they were taking heparin or warfarin, which could affect vitamin K metabolism. Subjects who had any of the following were also excluded: thyroid diseases, parathyroid diseases, abnormal calcium and bone metabolism, autoimmune diseases, renal, cardiovascular, cerebrovascular diseases, and malignant tumors.

2. Questionnaire and body measurement

Based on the questionnaire results and medical records, we investigated if the subjects were taking any medications for diabetes, high blood pressure, and hyperlipidemia. We also looked at histories of smoking or menopause. Subjects were deemed as post-menopausal if they had not menstruated for the past 12 months.

The subjects had a cuff of an appropriate size wrapped around their upper arms, and a mercury sphygmomanometer was used to measure their systolic and diastolic blood pressure, while sitting on a chair in a relaxed state.

Subjects took off their clothes and shoes, and changed into examination gowns. Their heights were measured to the nearest 0.1 cm and their weights to the nearest 0.1 kg, by using a Fatness Measuring system (Fanics, Busan, Korea). Body mass index (BMI) was measured by dividing the body mass (kg) by the square of the body height (m²).

3. Blood test

Blood sample was collected after the subjects fasted for 12 hr. The concentrations of calcium, phosphorus, glucose, and lipids and ALP concentration were measured by using an automatic chemical analyzer (AU-5400; Olympus Optical Co, Tokyo, Japan). Insulin concentration was measured through radioimmunoassay (RIA) by using a human insulin specific RIA kit (Linco Research Inc., St. Charles, MO, USA).

Osteocalcin concentration was measured under electrochemiluminescence immunoassay (ECLIA) by using a N-MID osteocalcin kit (Roche Diagnostics, Mannheim, Germany). By using fasting plasma glucose and insulin as indicators of insulin resistance, the HOMA-IR ([Fasting insulin (μIU/mL) × fasting plasma glucose (mmol/L)] / 22.5) was calculated.[11]

4. Coronary CT angiography

Using a 128 channel dual-source coronary CT angiogra-
phy (Somatom Definition®; Siemens Healthcare, Forchheim, Germany), coronary angiography was performed. A standard protocol for coronary angiography (128 × 0.6 mm slice collimation, 0.28 sec rotation time, 120 kVp tube voltage, 320 mA tube current) was followed.

A dual injector (Medrad, Pittsburgh, PA, USA) was used to inject a nonionic contrast agent (Iomeron 400, 400 mg/mL; Bracco, Milan, Italy), and images were obtained. Segment thickness and intervals were set at 0.75 mm and 0.5 mm, respectively for image reformating. An experienced radiology specialist checked for the presence of atherosclerotic plaques in the coronary arteries with the naked eye after the images were reformatted in three-dimensional Workstation. Subjects were diagnosed with atherosclerotic plaques in the coronary arteries if plaques were detected in CT-angiograms.

5. Statistics
The mean, standard deviation or proportions (%) were calculated according to the characteristics of the variables. The interquartile range (25%-75%) was indicated for variables that were not normally distributed. Variables that were determined to be non-normally distributed after a Kolmogorov-Smirnov test were log-transformed before analysis. The Independent t-test, χ² test, or the Mann–Whitney U-test were used depending on the characteristics of the variables to analyze for the differences between men and women. To study the correlation between serum osteocalcin levels and other variables, the Pearson correlation coefficient was used. To look for an independent relationship between serum osteocalcin concentration and other variables, a stepwise multiple regression analysis was performed; serum osteocalcin levels was the dependent variable, and other parameters were the independent variables.

To compare the variables between subjects with and those without arteriosclerotic plaques in the coronary arteries, independent t-test, χ² test, and Mann–Whitney U-test were performed. Logistic regression analysis was used, with the presence of atherosclerotic plaques set as the dependent variable. For the statistical analyses, the MedCalc version 16.4.3 Program (MedClac Software, Mariakerke, Belgium) was used, and the level of significance was set at below 0.05.

RESULTS

1. General characteristics of the study subjects
Subjects included 98 adult men and women (24 men and 74 women). The mean age was 53.5 ± 8.8 years. There was no significant difference in the age between the men and women (P = 0.091). Among the women, 21 were premenopausal, with their mean age being 43.7 ± 3.2 years. Fifty-three female subjects were post-menopausal, with their mean age being 58.6 ± 6.7 years.

The mean osteocalcin level of the total subjects was 20.2 ± 11.8 ng/mL. There was no significant difference in osteocalcin concentration between men and women (men 17.6 ± 5.3 ng/mL vs. women 21.1 ± 13.2 ng/mL; P = 0.213). The mean serum osteocalcin concentrations for premenopausal and postmenopausal women were 15.4 ± 3.4 ng/mL and 23.3 ± 14.9 ng/mL, respectively. The mean serum osteocalcin levels of postmenopausal women was significantly higher than that of the premenopausal women (P = 0.019).

There were no significant differences between men and women in the serum concentrations of calcium, phosphorus, and ALP, HOMA-IR, systolic and diastolic pressure, low-density cholesterol concentration, and BMI. However, significant differences were observed for high-density cholesterol and triglyceride levels (Table 1). Other general characteristics of the subjects are shown in Table 1.

2. The relationship between serum osteocalcin and other variables
Osteocalcin concentration showed a significant correlation with concentrations of serum calcium (r = 0.273, P = 0.007), phosphorus (r = 0.378, P < 0.001), and ALP (r = 0.705, P < 0.001), but was not associated with any other variables (Table 2).

In order to determine which independent variables were independently related to osteocalcin level, stepwise multiple regression analysis was performed using osteocalcin concentration as the dependent variable and other variables as the independent variables. Serum osteocalcin concentration was independently correlated to fasting blood glucose (β = -0.145, P = 0.001), ALP, and serum phosphorus and calcium concentrations, even after being adjusted for sex, age, and menopausal status. When HOMA-IR was used as independent variable instead of fasting blood glucose, to avoid multicollinearity, osteocalcin concentration showed an independent correlation with HOMA-IR (β = -1.794, P =
Table 1. General characteristics

| Variables                        | Total (n = 98) | Men (n = 24) | Women (n = 74) | P-value |
|----------------------------------|---------------|-------------|---------------|---------|
| Age (yr)                         | 53.5 ± 8.8    | 50.9 ± 7.5  | 54.4 ± 9.0    | 0.091   |
| Height (cm)                      | 160.3 ± 8.5   | 171.7 ± 4.6 | 156.6 ± 5.7   | <0.001  |
| Weight (kg)                      | 63.4 ± 12.2   | 75.5 ± 10.8 | 59.4 ± 9.8    | <0.001  |
| Body mass index (kg/m²)          | 24.6 ± 3.6    | 25.6 ± 3.5  | 24.2 ± 3.5    | 0.093   |
| Osteocalcin (ng/mL)              | 20.2 ± 11.8   | 17.6 ± 5.3  | 21.1 ± 13.2   | 0.213   |
| Alkaline phosphatase (IU/L)      | 63.7 ± 23.9   | 62.6 ± 16.6 | 64.1 ± 25.9   | 0.785   |
| Calcium (mg/dL)                  | 9.1 ± 0.4     | 9.2 ± 0.3   | 9.1 ± 0.4     | 0.222   |
| Phosphate (mg/dL)                | 3.7 ± 0.5     | 3.5 ± 0.5   | 3.7 ± 0.5     | 0.073   |
| Systolic blood pressure (mmHg)   | 114.4 ± 15.0  | 115.4 ± 11.9| 114.1 ± 16.0  | 0.707   |
| Diastolic blood pressure (mmHg)  | 76.1 ± 9.1    | 76.7 ± 7.5  | 75.9 ± 9.6    | 0.705   |
| Glucose (mg/dL)                  | 99.8 ± 20.6   | 99.7 ± 13.7 | 99.8 ± 22.4   | 0.988   |
| Insulin (uIU/mL)                 | 4.0 (2.4-6.7) | 4.3 (2.6-6.4)| 3.9 (3.0-7.1) | 0.676   |
| HOMA-IR<sup>a</sup>              | 1.0 (0.6-1.7) | 1.1 (0.6-1.5)| 0.9 (0.6-1.7) | 0.681   |
| Total cholesterol (mg/dL)        | 210.7 ± 42.7  | 210.3 ± 50.4| 210.9 ± 40.3  | 0.952   |
| HDL-cholesterol (mg/dL)          | 57.0 ± 14.5   | 48.7 ± 6.0  | 59.7 ± 15.4   | 0.001   |
| LDL-cholesterol (mg/dL)          | 141.5 ± 34.5  | 147.2 ± 39.6| 139.6 ± 32.7  | 0.350   |
| Triglyceride (mg/dL)<sup>b</sup> | 109.6 (86.5-152.9)| 115.4 (118.6-195.8) | 110.5 (98.2-134.7) | <0.001 |
| Diabetes medication, n (%)       | 6 (6.1)       | 1 (4.2)     | 5 (6.8)       | 0.429   |
| Hypertension medication, n (%)   | 18 (18.4)     | 5 (20.8)    | 13 (17.6)     | 0.721   |
| Dyslipidemia medication, n (%)   | 8 (8.2)       | 1 (4.2)     | 7 (9.5)       | 0.413   |
| Current smoking, n (%)           | 9 (9.2)       | 8 (33.3)    | 1 (1.4)       | <0.001  |
| Ex-smoker, n (%)                 | 8 (8.2)       | 8 (33.3)    | 0 (0.0)       | <0.001  |
| Menopause, n (%)                 | 53 (71.6)     | 31 (31.6)   | 10 (41.7)     | 0.230   |
| Coronary atherosclerosis, n (%)  | 11 (11.2)     | 10 (41.7)   | 21 (28.4)     |         |

The data is presented as mean ± standard deviation or number (%).<sup>a</sup>Median, interquartile range, logarithmically transformed before analysis. HOMA-IR, homeostasis model assessment of insulin resistance; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Table 2. Pearson correlation of serum osteocalcin levels with other variables

| Variables                        | r       | P-value |
|----------------------------------|---------|---------|
| Age (yr)                         | 0.080   | 0.435   |
| Body mass index                  | -0.099  | 0.334   |
| Alkaline phosphatase             | 0.705   | <0.001  |
| Calcium                          | 0.273   | 0.007   |
| Phosphate                        | 0.378   | <0.001  |
| Systolic blood pressure          | -0.044  | 0.666   |
| Diastolic blood pressure         | 0.020   | 0.845   |
| Glucose                          | -0.026  | 0.798   |
| Insulin<sup>a</sup>              | -0.163  | 0.110   |
| HOMA-IR<sup>a</sup>              | -0.162  | 0.111   |
| Total cholesterol                | -0.077  | 0.453   |
| HDL-cholesterol                  | 0.072   | 0.482   |
| LDL-cholesterol                  | -0.070  | 0.493   |
| Triglyceride<sup>a</sup>         | -0.028  | 0.781   |

<sup>a</sup>Logarithmically transformed before analysis. HOMA-IR, homeostasis model assessment of insulin resistance; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Table 3. Stepwise multiple regression for serum osteocalcin levels

| Independent variables | Coefficient (β) | P-value |
|-----------------------|-----------------|---------|
| Model 1               |                 |         |
| Glucose               | -0.145          | 0.001   |
| Alkaline phosphatase  | 0.356           | <0.001  |
| Calcium               | 4.438           | 0.006   |
| Phosphate             | 4.658           | 0.008   |
| Model 2               |                 |         |
| HOMA-IR<sup>a</sup>   | -1.794          | 0.027   |
| Alkaline phosphatase  | 0.330           | <0.001  |
| Phosphate             | 5.829           | 0.001   |

Dependent variable: osteocalcin level. Independent variables: Model 1 (age, sex, menopausal status body mass index [BMI], glucose, systolic blood pressure [SBP], diastolic blood pressure [DBP], total cholesterol, low-density lipoprotein [LDL]-cholesterol, high-density lipoprotein [HDL]-cholesterol, triglyceride [logarithmically transformed before analysis], smoking status, medication history of diabetes, hypertension, dyslipidemia), Model 2 (age, sex, menopausal status BMI, glucose or HOMA-IR [logarithmically transformed before analysis], SBP, DBP, total cholesterol, LDL-cholesterol, triglyceride [logarithmically transformed before analysis], smoking status, medication history of diabetes, hypertension, dyslipidemia).

<sup>a</sup>Logarithmically transformed before analysis. HOMA-IR, homeostasis model assessment of insulin resistance.
0.027), ALP, and blood phosphorus concentration (Table 3).

3. Comparison of variables between subjects with and those without arteriosclerotic plaques in the coronary arteries measured by coronary CT angiography

Atherosclerotic plaques in the coronary CT angiogram were detected in 31 subjects (10 men, 41.7% vs. 21 women, 28.4%), accounting for 31.6% of the total population. There were no differences in the prevalence of atherosclerotic plaques in men and women \((P=0.230)\) (Table 1). However, the mean age \((P=0.002)\) and proportion of postmenopausal women \((P=0.024)\) were significantly higher in the group with atherosclerotic plaques (Table 4).

Serum osteocalcin levels did not differ significantly between the subjects with or without atherosclerotic plaques \((20.1 \pm 10.6 \text{ ng/mL vs. } 20.5 \pm 14.2 \text{ ng/mL}; P=0.859)\). Glucose \((P=0.002)\), systolic pressure \((P=0.018)\), and diastolic pressure \((P=0.026)\) significantly increased in the group with atherosclerotic plaques compared to the group without (Table 4). Stepwise logistic analysis showed that age, fasting blood glucose concentration, and smoking status were independently correlated with the presence of ath-

### Table 4. Comparison the variables according to presence of coronary plaque

| Variables                      | Without coronary plaque (n=67) | With coronary plaque (n=31) | P-value |
|--------------------------------|-------------------------------|----------------------------|---------|
| Age (yr)                       | 51.7 ± 8.7                    | 57.5 ± 7.6                 | 0.002   |
| Body mass index (kg/m²)        | 24.3 ± 3.7                    | 25.1 ± 3.1                 | 0.336   |
| Osteocalcin (ng/mL)            | 20.1 ± 10.6                   | 20.5 ± 14.2                | 0.859   |
| Alkaline phosphatase (IU/L)    | 61.5 ± 20.5                   | 68.5 ± 29.7                | 0.180   |
| Calcium (mg/dL)                | 9.1 ± 0.4                     | 9.2 ± 0.4                  | 0.333   |
| Phosphate (mg/dL)              | 3.7 ± 0.5                     | 3.7 ± 0.5                  | 0.502   |
| Systolic blood pressure (mmHg) | 112.0 ± 15.1                  | 119.6 ± 13.7               | 0.018   |
| Diastolic blood pressure (mmHg)| 74.7 ± 9.5                    | 79.0 ± 7.4                 | 0.026   |
| Glucose (mg/dL)                | 95.5 ± 11.5                   | 109.0 ± 30.8               | 0.002   |
| Insulin (μIU/mL)a               | 3.9 (2.2-6.2)                 | 5.1 (2.8-7.4)              | 0.650   |
| HOMA-IRa                       | 0.9 (0.5-1.5)                 | 1.5 (0.6-1.9)              | 0.171   |
| Total cholesterol (mg/dL)      | 212.6 ± 37.1                  | 206.7 ± 53.4               | 0.527   |
| HDL-cholesterol (mg/dL)        | 58.7 ± 15.1                   | 53.3 ± 12.6                | 0.082   |
| LDL-cholesterol (mg/dL)        | 143.5 ± 30.9                  | 137.1 ± 41.4               | 0.400   |
| Triglyceride (mg/dL)a          | 109.2 (83.9-144.0)            | 122.1 (90.3-166.0)         | 0.208   |
| Diabetes medication, n (%)     | 2 (3.0)                       | 5 (16.1)                   | 0.051   |
| Hypertension medication, n (%) | 9 (13.4)                      | 9 (29.0)                   | 0.065   |
| Dyslipidemia medication, n (%) | 3 (4.5)                       | 5 (16.1)                   | 0.051   |
| Current smoking, n (%)         | 4 (6.0)                       | 5 (16.1)                   | 0.234   |
| Ex-smoker, n (%)               | 5 (7.5)                       | 3 (9.7)                    |         |
| Men, n (%)                     | 14 (20.9)                     | 10 (32.3)                  | 0.226   |
| Women, n (%)                   | 53 (79.1)                     | 21 (67.7)                  |         |
| Menopause, n (%)               | 34 (50.7)                     | 19 (61.3)                  | 0.024   |

The data is presented as mean ± standard deviation or number (%).

*aMedian, interquartile range, logarithmically transformed before analysis.

HOMA-IR: homeostasis model assessment of insulin resistance; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

### Table 5. Logistic regression analysis for the variables between subjects with and those without arteriosclerotic plaques in the coronary arteries

| Independent variables | Coefficient (β) | P-value |
|-----------------------|-----------------|---------|
| Age                   | 0.092           | 0.003   |
| Glucose               | 0.049           | 0.011   |
| Current smoking       | 1.782           | 0.020   |

Dependent variable: presence of coronary plaque.

Independent variables: osteocalcin, age, sex, menopausal status body mass index, glucose or homeostasis model assessment of insulin resistance (logarithmically transformed before analysis), systolic blood pressure, diastolic blood pressure, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride (logarithmically transformed before analysis), smoking status, medication history of diabetes, hypertension, dyslipidemia.
erosclerotic plaques, but osteocalcin was not significant dependent variable in this model after controlling for other variables (Table 5).

DISCUSSION

Osteocalcin concentrations reflect the rate of bone formation and the treatment for osteoporosis such as bisphosphonate change the osteocalcin levels.[12] ALP is also a useful index for monitoring changes in bone turnover.[13] Plasma ALP concentration mostly originates from the bones and the liver and especially bone-specific ALP reflects osteoblast activity.[14]

In this study, serum osteocalcin levels showed a significant correlation with ALP, calcium, and phosphorus concentration. This is a predictable result, considering osteocalcin is a bone turnover marker.

Although there was no significant difference in serum osteocalcin levels between men and women, significantly higher osteocalcin levels were observed in postmenopausal women than premenopausal women. A previous study showed decreased osteocalcin concentration with increased age, but osteocalcin levels showed an increasing trend in postmenopausal women and men over the age of 70.[15]

On multiple regression analysis, serum osteocalcin level showed negative correlation with fasting blood glucose and HOMA-IR after adjusting for age, sex, and menopausal status and this correlation was independent with ALP, calcium, and phosphorus concentration. This result shows that osteocalcin might be related to glucose metabolism and insulin resistance independently from its role as a bone turnover marker that reflects the rate of bone formation.

Many clinical studies have reported that a reduction in serum osteocalcin is related to increased incidences of high blood glucose, insulin resistance, obesity, metabolic syndrome and has important role in energy metabolism.[4,5, 16-19] In this study, we found fasting blood glucose and insulin resistance were related to osteocalcin concentration. In contrast, BMI, history of diabetes, hyperlipidemia, high blood pressure, and plasma lipid concentration were not related to osteocalcin concentration. It is possible that there were not enough study subjects to reveal a correlation. Although both cardiovascular diseases and osteoporosis are diseases whose prevalence increases with age, bone mineral density was shown in previous studies to be inversely correlated to the advanced atherosclerosis and mortality, even after adjusting for age.[20,21]

Lately, osteocalcin has been gaining attention as a connecting factor between cardiovascular diseases and bone metabolism, and numerous cross-sectional studies and longitudinal studies have shown that a decrease in serum osteocalcin level is associated with increased rates of cardiovascular diseases. A prospective 10-year cohort study involving 774 men reported that the group with high serum osteocalcin concentration had the lowest rate of calcification in the abdominal aorta, and also the lowest death rate.[22] In a cross-sectional study with 461 Chinese subjects, the group diagnosed with atherosclerotic plaques detected though angiography had increased osteocalcin concentration compared to the group without atherosclerotic plaques even after adjusting for cardiovascular risk factors.[23]

A recent cross-sectional study with Korean subjects also reported that undercarboxylated osteocalcin concentrations, as well as the ratio between under-carboxylated osteocalcin and total osteocalcin concentration, were independently associated with known risk factors of cardiovascular diseases and bone density, and were negatively correlated with coronary calcification in men.[6]

No definite mechanism shows a clear correlation between osteocalcin levels and cardiovascular diseases. However, cardiovascular calcification is one of the pathological changes of cardiovascular diseases, and an imbalance in osteocalcin concentration and cardiovascular mineralization may induce such changes.[24] Some endothelial progenitor cells involved in ischemic tissue regeneration can secrete osteocalcin, and although a recent study has reported that osteocalcin-secreting endothelial progenitor cells are related to unstable coronary heart disease, the role of these cells in the occurrence of arteriosclerosis is still unclear.[25]

In this study, the serum osteocalcin levels were not significantly different between subjects with and those without atherosclerotic plaques in the coronary arteries.

The conflicting results of this study compared to the above mentioned studies may be caused from the difference of method to diagnose coronary atherosclerosis. In this study, we used coronary MDCT angiography to reveal relationship between the presence of coronary atherosclerotic plaques and osteocalcin concentration. MDCT can detect both calcified and non-calcified plaque compared to coronary cal-
Osteocalcin, IR, Coronary Atherosclerosis

The concentration of osteocalcin is mainly involved in bone mineralization, and undercarboxylated osteocalcin, which is mainly involved in energy metabolism and controlled by vitamin K concentration.[2,3,26] Osteocalcin reflects bone turnover and bone density; bone density and atherosclerosis share various mutual risk factors such as age, smoking, menopause, diet, exercise, and physical activity. It is possible that the data were not adjusted enough for these confounding variables; thus, we might not be able to observe any difference in osteocalcin concentration between the groups.

However, a few cohort studies have reported an absent correlation between osteocalcin and the incidence of cardiovascular diseases.[10] Similarly, a cross-sectional study has reported that osteocalcin concentration in postmenopausal women was positively correlated with the prevalence of coronary atherosclerosis, contrary to the results of previous studies.[27] There has also been a report that in both healthy men and premenopausal and postmenopausal women, osteocalcin has no independent correlation with the carotid intima-media thickness.[28] Therefore, osteocalcin concentration may have a miniscule or limited impact on the development of atherosclerosis.

A prospective study that was carried out for five years and involved 3,522 elderly men reported that serum osteocalcin levels may be used to predict the mortality rate of cardiovascular diseases at both low and high concentrations, resulting in a U-shaped relationship.[29] Another cohort study with 1,319 subjects reported that the higher the concentration of osteocalcin, the lower the risk for cardiovascular diseases in men, and the higher the risk in women.[30] Therefore, the relationship between osteocalcin and cardiovascular disease risks may vary depending on gender, race, and the characteristics of a subject group.

In conclusion, serum osteocalcin level was inversely associated with fasting glucose level and insulin resistance measured by HOMA-IR, suggesting that osteocalcin is important for glucose metabolism. However, in this study, no significant difference was observed in the serum osteocalcin level according to the presence of coronary atherosclerotic plaques.

It would be necessary to assess the clinical significance of osteocalcin through large-scale prospective studies involving diverse groups of subjects.

REFERENCES

1. Kanazawa I. Osteocalcin as a hormone regulating glucose metabolism. World J Diabetes 2015;6:1345-54.
2. Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007;130:456-69.
3. Ferron M, Hinoi E, Karsenty G, et al. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A 2008;105:5266-70.
4. Kindblom JM, Ohlsson C, Ljunggren O, et al. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res 2009;24:785-91.
5. Fernández-Real JM, Izquierdo M, Ortega F, et al. The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J Clin Endocrinol Metab 2009;94:237-45.
6. Choi BH, Joo NS, Kim MJ, et al. Coronary artery calcification is associated with high serum concentration of undercarboxylated osteocalcin in asymptomatic Korean men. Clin Endocrinol (Oxf) 2015;83:320-6.
7. Kim KJ, Kim KM, Park KH, et al. Aortic calcification and bone metabolism: the relationship between aortic calcification, BMD, vertebral fracture, 25-hydroxyvitamin D, and osteocalcin. Calcif Tissue Int 2012:91:370-8.
8. Sheng L, Cao W, Cha B, et al. Serum osteocalcin level and its association with carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol 2013;12:22.
9. Yang R, Ma X, Dou J, et al. Relationship between serum osteocalcin levels and carotid intima-media thickness in
Chinese postmenopausal women. Menopause 2013;20:1194-9.

10. Hwang YC, Kang M, Cho IJ, et al. Association between the circulating total osteocalcin level and the development of cardiovascular disease in middle-aged men: a mean 8.7-year longitudinal follow-up study. J Atheroscler Thromb 2015;22:136-43.

11. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.

12. Hong SH, Koo JW, Hwang JK, et al. Changes in serum osteocalcin are not associated with changes in glucose or insulin for osteoporotic patients treated with bisphosphonate. J Bone Metab 2013;20:37-41.

13. Atalay S, Elci A, Kayadibi H, et al. Diagnostic utility of osteocalcin, undercarboxylated osteocalcin, and alkaline phosphatase for osteoporosis in premenopausal and postmenopausal women. Ann Lab Med 2012;32:23-30.

14. Leung KS, Fung KP, Sher AH, et al. Plasma bone-specific alkaline phosphatase as an indicator of osteoblastic activity. J Bone Joint Surg Br 1993;75:288-92.

15. Gundberg CM, Looker AC, Nieman SD, et al. Patterns of osteocalcin and bone specific alkaline phosphatase by age, gender, and race or ethnicity. Bone 2002;31:703-8.

16. Lee SW, Jo HH, Kim MR, et al. Association between obesity, metabolic risks and serum osteocalcin level in postmenopausal women. Gynecol Endocrinol 2012;28:472-7.

17. Kim SH, Lee JW, Im JA, et al. Serum osteocalcin is related to abdominal obesity in Korean obese and overweight men. Clin Chim Acta 2010;411:2054-7.

18. Oosterwerff MM, van Schoor NM, Lips P, et al. Osteocalcin as a predictor of the metabolic syndrome in older persons: a population-based study. Clin Endocrinol (Oxf) 2013;78:242-7.

19. Zanatta LC, Boguszewski CL, Borba VZ, et al. Osteocalcin, energy and glucose metabolism. Arq Bras Endocrinol Metabol 2014;58:444-51.

20. Tankò LB, Bagger YZ, Christiansen C. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 2003;73:15-20.

21. Trivedi DP, Khaw KT. Bone mineral density at the hip predicts mortality in elderly men. Osteoporos Int 2001;12:259-65.

22. Confavreux CB, Szulc P, Casey R, et al. Higher serum osteocalcin is associated with lower abdominal aortic calcification progression and longer 10-year survival in elderly men of the MINOS cohort. J Clin Endocrinol Metab 2013;98:1084-92.

23. Zhang Y, Qi L, Gu W, et al. Relation of serum osteocalcin level to risk of coronary heart disease in Chinese adults. Am J Cardiol 2010;106:1461-5.

24. Evrard S, Delanaye P, Kamel S, et al. Vascular calcification: from pathophysiology to biomarkers. Clin Chim Acta 2015;438:401-14.

25. Flammer AJ, Gössl M, Widmer RJ, et al. Osteocalcin positive CD133+/CD34-/KDR+ progenitor cells as an independent marker for unstable atherosclerosis. Eur Heart J 2012;33:2963-9.

26. Patti A, Gennari L, Merlotti D, et al. Endocrine actions of osteocalcin. Int J Endocrinol 2013;2013:846480.

27. Montalcini T, Emanuele V, Ceravolo R, et al. Relation of low bone mineral density and carotid atherosclerosis in postmenopausal women. Am J Cardiol 2004;94:266-9.

28. Luo Y, Ma X, Hao Y, et al. Relationship between serum osteocalcin level and carotid intima-media thickness in a metabolically healthy Chinese population. Cardiovasc Diabetol 2015;14:82.

29. Yeap BB, Chubb SA, Flicker L, et al. Associations of total osteocalcin with all-cause and cardiovascular mortality in older men. The Health In Men Study. Osteoporos Int 2012;23:599-606.

30. Holvik K, van Schoor NM, Eekhoff EM, et al. Plasma osteocalcin levels as a predictor of cardiovascular disease in older men and women: a population-based cohort study. Eur J Endocrinol 2014;171:161-70.